Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
Data ReadoutpositiveretatrutidePositive
AI Analysis
Summary
Lilly's retatrutide demonstrated substantial weight loss (49.6 lbs average) and A1C reduction in the TRIUMPH-2 trial for patients with obesity and type 2 diabetes, with over half no longer meeting obesity BMI criteria at the 12 mg dose.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
TRIUMPH-2 trial showed retatrutide 12 mg achieved average weight loss of 49.6 lbs (20.8%) over 80 weeks with A1C reduction; more than half of participants no longer met BMI criteria for obesity
Importance:8/10
Sentiment:
0.85
obesitytype 2 diabetesweight losstriple agonistclinical trialGLP-1
Related Companies
Read the original article
Published by PR Newswire Biotech on September 29, 2026 10:00 PM